{
    "Trade/Device Name(s)": [
        "ACESO Early Pregnancy Test"
    ],
    "Submitter Information": "Aceso Laboratories, Inc.",
    "510(k) Number": "K234152",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150022"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCX"
    ],
    "Summary Letter Date": "April 5, 2024",
    "Summary Letter Received Date": "February 22, 2024",
    "Submission Date": "March 22, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1155"
    ],
    "Regulation Name(s)": [
        "Human Chorionic Gonadotropin (HCG) Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Human Chorionic Gonadotropin (hCG)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow chromatographic immunoassay",
        "Immunochromatographic assay"
    ],
    "Methodologies": [
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Test",
        "Strip",
        "Cassette",
        "Midstream"
    ],
    "Document Summary": "FDA 510(k) summary for ACESO Early Pregnancy Test for qualitative urine detection of hCG as an aid in early pregnancy detection",
    "Indications for Use Summary": "Intended for qualitative detection of hCG in urine to aid early detection of pregnancy, for home use only, usable as early as five days before the expected period",
    "fda_folder": "Clinical Chemistry"
}